Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis

Journal of Medicinal Chemistry

Volumn 59, Issue 13, 2016, Pages 6531-6546

  Vidadala, Rama Subba Rao ^b   Rivas, Kasey L ^a   Ojo, Kayode K ^a   Hulverson, Matthew A ^a   Zambriski, Jennifer A ^e   Bruzual, Igor ^d   Schultz, Tracey L ^f   Huang, Wenlin ^a   Zhang, Zhongsheng ^a   Scheele, Suzanne ^c   DeRocher, Amy E ^c   Choi, Ryan ^a   Barrett, Lynn K ^a   Siddaramaiah, Latha Kallur ^a   Hol, Wim G J ^a   Fan, Erkang ^a   Merritt, Ethan A ^a   Parsons, Marilyn ^b,c   Freiberg, Gail ^g   Marsh, Kennan ^g   Kempf, Dale J ^g   Carruthers, Vern B ^f   Isoherranen, Nina ^b   Doggett, J Stone ^d   Van Voorhis, Wesley C ^a,b   Maly, Dustin J ^a,b   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e WASHINGTON STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL HERG; PROTEIN KINASE INHIBITOR; TOXOPLASMA GONDII CALCIUM DEPENDENT PROTEIN KINASE 1 INHIBITOR; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; CALCIUM-DEPENDENT PROTEIN KINASE; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE ACTIVITY; IC50; MOUSE; NONHUMAN; PERITONEAL FLUID; SPLEEN; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOG; DOSE RESPONSE; DRUG EFFECTS; DRUG SENSITIVITY; ENZYMOLOGY; FEMALE; HAPLORHINI; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; TOXOPLASMA;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HAPLORHINI; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84978476937     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00760     Document Type: Article

References (36)

1. Tenter, A. M.; Heckeroth, A. R.; Weiss, L. M. Toxoplasma gondii: from animals to humans Int. J. Parasitol. 2000, 30, 1217-1258 10.1016/S0020-7519(00)00124-7
2. Pappas, G.; Roussos, N.; Falagas, M. E. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis Int. J. Parasitol. 2009, 39, 1385-1394 10.1016/j.ijpara.2009.04.003
3. Schwartzman, J. D.; Maguire, J. H. Toxoplasmosis. In Tropical Infectious Diseases: Principles, Pathogens and Practice, 3 rd ed.; W. B. Saunders: Edinburgh, U.K., 2011; Chapter 103, pp 722-728.
4. Dupont, C. D.; Christian, D. A.; Hunter, C. A. Immune response and immunopathology during toxoplasmosis Semin. Immunopathol. 2012, 34, 793-813 10.1007/s00281-012-0339-3
5. Blanchard, N.; Dunay, I. R.; Schluter, D. Persistence of Toxoplasma gondii in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system Parasite Immunol. 2015, 37, 150-158 10.1111/pim.12173
6. Flegr, J.; Prandota, J.; Sovickova, M.; Israili, Z. H. Toxoplasmosis-a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries PLoS One 2014, 9, e90203 10.1371/journal.pone.0090203
7. Jones, J. L.; Muccioli, C.; Belfort, R., Jr.; Holland, G. N.; Roberts, J. M.; Silveira, C. Recently acquired Toxoplasma gondii infection, Brazil Emerging Infect. Dis. 2006, 12, 582-587 10.3201/eid1204.051081
8. Carlier, Y.; Truyens, C.; Deloron, P.; Peyron, F. Congenital parasitic infections: a review Acta Trop. 2012, 121, 55-70 10.1016/j.actatropica.2011.10.018
9. Dubey, J. P.; Jones, J. L. Toxoplasma gondii infection in humans and animals in the United States Int. J. Parasitol. 2008, 38, 1257-1278 10.1016/j.ijpara.2008.03.007
10. Wei, H. X.; Wei, S. S.; Lindsay, D. S.; Peng, H. J. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans PLoS One 2015, 10, e0138204 10.1371/journal.pone.0138204
11. Kaplan, J. E.; Benson, C.; Holmes, K. K.; Brooks, J. T.; Pau, A.; Masur, H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America Morbidity Mortality Wkly Rep 2009, 58, 1-207
12. Kieschnick, H.; Wakefield, T.; Narducci, C. A.; Beckers, C. Toxoplasma gondii attachment to host cells is regulated by a calmodulin-like domain protein kinase J. Biol. Chem. 2001, 276, 12369-12377 10.1074/jbc.M011045200
13. Lourido, S.; Shuman, J.; Zhang, C.; Shokat, K. M.; Hui, R.; Sibley, L. D. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma Nature 2010, 465, 359-362 10.1038/nature09022
14. Lourido, S.; Zhang, C.; Lopez, M. S.; Tang, K.; Barks, J.; Wang, Q.; Wildman, S. A.; Shokat, K. M.; Sibley, L. D. Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii J. Med. Chem. 2013, 56, 3068-3077 10.1021/jm4001314
15. Doggett, J. S.; Ojo, K. K.; Fan, E.; Maly, D. J.; Van Voorhis, W. C. Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection Antimicrob. Agents Chemother. 2014, 58, 3547-3549 10.1128/AAC.01823-13
16. Zhang, Z.; Ojo, K. K.; Johnson, S. M.; Larson, E. T.; He, P.; Geiger, J. A.; Castellanos-Gonzalez, A.; White, A. C., Jr.; Parsons, M.; Merritt, E. A.; Maly, D. J.; Verlinde, C. L.; Van Voorhis, W. C.; Fan, E. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1 Bioorg. Med. Chem. Lett. 2012, 22, 5264-5267 10.1016/j.bmcl.2012.06.050
17. Zhang, Z.; Ojo, K. K.; Vidadala, R.; Huang, W.; Geiger, J. A.; Scheele, S.; Choi, R.; Reid, M. C.; Keyloun, K. R.; Rivas, K.; Siddaramaiah, L. K.; Comess, K. M.; Robinson, K. P.; Merta, P. J.; Kifle, L.; Hol, W. G.; Parsons, M.; Merritt, E. A.; Maly, D. J.; Verlinde, C. L.; Van Voorhis, W. C.; Fan, E. Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold ACS Med. Chem. Lett. 2014, 5, 40-44 10.1021/ml400315s
18. Murphy, R. C.; Ojo, K. K.; Larson, E. T.; Castellanos-Gonzalez, A.; Perera, B. G.; Keyloun, K. R.; Kim, J. E.; Bhandari, J. G.; Muller, N. R.; Verlinde, C. L.; White, A. C., Jr.; Merritt, E. A.; Van Voorhis, W. C.; Maly, D. J. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii ACS Med. Chem. Lett. 2010, 1, 331-335 10.1021/ml100096t
19. Johnson, S. M.; Murphy, R. C.; Geiger, J. A.; DeRocher, A. E.; Zhang, Z.; Ojo, K. K.; Larson, E. T.; Perera, B. G.; Dale, E. J.; He, P.; Reid, M. C.; Fox, A. M.; Mueller, N. R.; Merritt, E. A.; Fan, E.; Parsons, M.; Van Voorhis, W. C.; Maly, D. J. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity J. Med. Chem. 2012, 55, 2416-2426 10.1021/jm201713h
20. Ojo, K. K.; Larson, E. T.; Keyloun, K. R.; Castaneda, L. J.; Derocher, A. E.; Inampudi, K. K.; Kim, J. E.; Arakaki, T. L.; Murphy, R. C.; Zhang, L.; Napuli, A. J.; Maly, D. J.; Verlinde, C. L.; Buckner, F. S.; Parsons, M.; Hol, W. G.; Merritt, E. A.; Van Voorhis, W. C. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors Nat. Struct. Mol. Biol. 2010, 17, 602-607 10.1038/nsmb.1818
21. Ojo, K. K.; Reid, M. C.; Kallur Siddaramaiah, L.; Muller, J.; Winzer, P.; Zhang, Z.; Keyloun, K. R.; Vidadala, R. S.; Merritt, E. A.; Hol, W. G.; Maly, D. J.; Fan, E.; Van Voorhis, W. C.; Hemphill, A. Neospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy PLoS One 2014, 9, e92929 10.1371/journal.pone.0092929
22. Winzer, P.; Muller, J.; Aguado-Martinez, A.; Rahman, M.; Balmer, V.; Manser, V.; Ortega-Mora, L. M.; Ojo, K. K.; Fan, E.; Maly, D. J.; Van Voorhis, W. C.; Hemphill, A. In vitro and in vivo effects of the bumped kinase inhibitor 1294 in the related cyst-forming Apicomplexans Toxoplasma gondii and Neospora caninum Antimicrob. Agents Chemother. 2015, 59, 6361-6374 10.1128/AAC.01236-15
23. Ojo, K. K.; Eastman, R. T.; Vidadala, R.; Zhang, Z.; Rivas, K. L.; Choi, R.; Lutz, J. D.; Reid, M. C.; Fox, A. M.; Hulverson, M. A.; Kennedy, M.; Isoherranen, N.; Kim, L. M.; Comess, K. M.; Kempf, D. J.; Verlinde, C. L.; Su, X. Z.; Kappe, S. H.; Maly, D. J.; Fan, E.; Van Voorhis, W. C. A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation J. Infect. Dis. 2014, 209, 275-284 10.1093/infdis/jit522
24. van Noord, C.; Eijgelsheim, M.; Stricker, B. H. Drug- and non-drug-associated QT interval prolongation Br. J. Clin. Pharmacol. 2010, 70, 16-23 10.1111/j.1365-2125.2010.03660.x
25. Larson, E. T.; Ojo, K. K.; Murphy, R. C.; Johnson, S. M.; Zhang, Z.; Kim, J. E.; Leibly, D. J.; Fox, A. M.; Reid, M. C.; Dale, E. J.; Perera, B. G.; Kim, J.; Hewitt, S. N.; Hol, W. G.; Verlinde, C. L.; Fan, E.; Van Voorhis, W. C.; Maly, D. J.; Merritt, E. A. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1 J. Med. Chem. 2012, 55, 2803-2810 10.1021/jm201725v
26. Vidadala, R. S.; Ojo, K. K.; Johnson, S. M.; Zhang, Z.; Leonard, S. E.; Mitra, A.; Choi, R.; Reid, M. C.; Keyloun, K. R.; Fox, A. M.; Kennedy, M.; Silver-Brace, T.; Hume, J. C.; Kappe, S.; Verlinde, C. L.; Fan, E.; Merritt, E. A.; Van Voorhis, W. C.; Maly, D. J. Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes Eur. J. Med. Chem. 2014, 74, 562-573 10.1016/j.ejmech.2013.12.048
27. Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation J. Biol. Chem. 1996, 271, 695-701 10.1074/jbc.271.2.695
28. Bridal, T. R.; Margulis, M.; Wang, X.; Donio, M.; Sorota, S. Comparison of human Ether-a-go-go related gene screening assays based on IonWorks Quattro and thallium flux Assay Drug Dev. Technol. 2010, 8, 755-765 10.1089/adt.2010.0267
29. Bowes, J.; Brown, A. J.; Hamon, J.; Jarolimek, W.; Sridhar, A.; Waldron, G.; Whitebread, S. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat. Rev. Drug Discovery 2012, 11, 909-22 10.1038/nrd3845
30. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583 10.1021/jm060642i
31. Cheng, Y.; Brown, J.; Judd, T. C.; Lopez, P.; Qian, W.; Powers, T. S.; Chen, J. J.; Bartberger, M. D.; Chen, K.; Dunn, R. T.; Epstein, O.; Fremeau, R. T., Jr.; Harried, S.; Hickman, D.; Hitchcock, S. A.; Luo, Y.; Minatti, A. E.; Patel, V. F.; Vargas, H. M.; Wahl, R. C.; Weiss, M. M.; Wen, P. H.; White, R. D.; Whittington, D. A.; Zheng, X. M.; Wood, S. An orally available BACE1 inhibitor that affords robust CNS Aβ reduction without cardiovascular liabilities ACS Med. Chem. Lett. 2015, 6, 210-215 10.1021/ml500458t
32. Epstein, O.; Bryan, M. C.; Cheng, A. C.; Derakhchan, K.; Dineen, T. A.; Hickman, D.; Hua, Z.; Human, J. B.; Kreiman, C.; Marx, I. E.; Weiss, M. M.; Wahl, R. C.; Wen, P. H.; Whittington, D. A.; Wood, S.; Zheng, X. M.; Fremeau, R. T., Jr.; White, R. D.; Patel, V. F. Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors J. Med. Chem. 2014, 57, 9796-9810 10.1021/jm501266w
33. Keyloun, K. R.; Reid, M. C.; Choi, R.; Song, Y.; Fox, A. M.; Hillesland, H. K.; Zhang, Z.; Vidadala, R.; Merritt, E. A.; Lau, A. O.; Maly, D. J.; Fan, E.; Barrett, L. K.; Van Voorhis, W. C.; Ojo, K. K. The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites Parasitology 2014, 141, 1499-1509 10.1017/S0031182014000857
34. Doggett, J. S.; Nilsen, A.; Forquer, I.; Wegmann, K. W.; Jones-Brando, L.; Yolken, R. H.; Bordón, C.; Charman, S. A.; Katneni, K.; Schultz, T.; Burrows, J. N.; Hinrichs, D. J.; Meunier, B.; Carruthers, V. B.; Riscoe, M. K. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 15936-15941 10.1073/pnas.1208069109
35. Edvinsson, B.; Lappalainen, M.; Evengård, B. ESCMID Study Group for Toxoplasmosis. Real-time PCR targeting a 529-bp repeat element for diagnosis of toxoplasmosis Clin. Microbiol. Infect. 2006, 12, 131-136 10.1111/j.1469-0691.2005.01332.x
36. Ollivett, T. L.; Nydam, D. V.; Bowman, D. D.; Zambriski, J. A.; Bellosa, M. L.; linden, T. C.; Divers, T. J. Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves J. Dairy Sci. 2009, 92, 1643-1648 10.3168/jds.2008-1474